RhumbLine Advisers
CAI

RhumbLine Advisers’s Caris Life Sciences CAI Stock Holding History

RhumbLine Advisers’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.33M Buy
74,622
+51,241
+219% +$1.12M ﹤0.01% 2053
2025
Q4 		$631K Buy
23,381
+1,884
+9% +$53.1K ﹤0.01% 2524
2025
Q3 		$650K Buy
+21,497
New +$686K ﹤0.01% 2518

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

RhumbLine Advisers's CAI Position: Q1 2026 in Review

RhumbLine Advisers increased its Caris Life Sciences (CAI) stake by 219% in Q1 2026, buying an estimated $1.12M and bringing the position to 74,622 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2053.

RhumbLine Advisers first reported a position in CAI in Q3 2025 and has held it in 3 quarters since. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • RhumbLine Advisers held 74,622 shares of Caris Life Sciences worth $1.33M as of Q1 2026.
  • RhumbLine Advisers bought 51,241 Caris Life Sciences shares in Q1 2026, an estimated $1.12M.
  • Caris Life Sciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2053 holding.
  • RhumbLine Advisers first reported a position in Caris Life Sciences in Q3 2025 and has held it in 3 quarters since.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.